Nanosyn Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
75
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
- Investments
-
2
Nanosyn General Information
Description
Provider of chemistry and biology services catering to small to mid-sized pharma and biotech companies. The company offers contract development and manufacturing, custom synthesis, process research and development, formulation and biology services, thereby helping customers from early-stage discovery, through clinical trials, formulation and regulatory approval.
Contact Information
Website
www.nanosyn.com(Operating Subsidiary)
Corporate Office
- 3100 Central Expressway
- Santa Clara, CA 95051
- United States
Corporate Office
- 3100 Central Expressway
- Santa Clara, CA 95051
- United States
Nanosyn Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nanosyn Comparisons
Industry
Financing
Details
Nanosyn Competitors (48)
One of Nanosyn’s 48 competitors is Selvita, a Corporation company based in Krakow, Poland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Selvita | Corporation | Krakow, Poland | ||||
| Prestwick Chemical | Corporate Backed or Acquired | Illkirch, France | ||||
| Inotiv | Formerly PE-Backed | West Lafayette, IN | ||||
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany |
Nanosyn Patents
Nanosyn Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11339126-B2 | Compounds for the reducing lipotoxic damage | Active | 12-Jul-2017 | ||
| US-11623915-B2 | Compounds for the reducing lipotoxic damage | Active | 12-Jul-2017 | ||
| US-20210139421-A1 | Compounds for the reducing lipotoxic damage | Active | 12-Jul-2017 | ||
| US-20220324797-A1 | Compounds for the reducing lipotoxic damage | Active | 12-Jul-2017 | ||
| WO-2018175906-A1 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | Inactive | 24-Mar-2017 | C07D487/04 |
Nanosyn Signals
Nanosyn Acquisitions (2)
Nanosyn’s most recent deal was a Merger/Acquisition with Seres Labratories. The deal was made on 01-Mar-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Seres Labratories | 01-Mar-2009 | Merger/Acquisition | Other Commercial Services | ||
| Amphora Discovery | 21-Oct-2008 | Merger/Acquisition | Drug Discovery |
Nanosyn FAQs
-
When was Nanosyn founded?
Nanosyn was founded in 1998.
-
Where is Nanosyn headquartered?
Nanosyn is headquartered in Santa Clara, CA.
-
What is the size of Nanosyn?
Nanosyn has 75 total employees.
-
What industry is Nanosyn in?
Nanosyn’s primary industry is Drug Discovery.
-
Is Nanosyn a private or public company?
Nanosyn is a Private company.
-
What is Nanosyn’s current revenue?
The current revenue for Nanosyn is .
-
Who are Nanosyn’s competitors?
Selvita, Prestwick Chemical, Inotiv, Sygnature Discovery, and Evotec are some of the 48 competitors of Nanosyn.
-
When was Nanosyn acquired?
Nanosyn was acquired on 11-Oct-2021.
-
Who acquired Nanosyn?
Nanosyn was acquired by Element Materials Technology (London).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process